Clinical Trials
3
Active:1
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 2
2 (100.0%)Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Phase 2
Recruiting
- Conditions
- PericarditisPericarditis AcuteRecurrent Pericarditis
- Interventions
- Drug: KPL-387Drug: Placebo
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Kiniksa Pharmaceuticals International, plc
- Target Recruit Count
- 165
- Registration Number
- NCT07010159
- Locations
- πΊπΈ
Investigational Site 001, Columbus, Georgia, United States
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Active, not recruiting
- Conditions
- Recurrent Pericarditis
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Kiniksa Pharmaceuticals International, plc
- Target Recruit Count
- 500
- Registration Number
- NCT04687358
- Locations
- πΊπΈ
Alaska Heart & Vascular Institute, Anchorage, Alaska, United States
πΊπΈPima Heart and Vascular, Tucson, Arizona, United States
πΊπΈUniversity of California San Diego Medical Center, La Jolla, California, United States
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Kiniksa Pharmaceuticals International, plc
- Target Recruit Count
- 814
- Registration Number
- NCT04447469
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈSHARP Health Care, San Diego, California, United States
πΊπΈAffinity Health, Chicago, Illinois, United States
News
No news found